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Background: Donor chimerism (the presence of donor cells of bone matTOW 
origin) is present for years after transplantation in recipients of solid organs. 
In lung recipients, chimerism is associated with a lower incidence of chron-
ic rejection. To augment donor chimerism with the aim to enhance graft 
acceptance and to reduce immunosuppression, we initiated a trial combining 
infusion of donor bone matTOW with heart transplantation. Reported herein 
are the intermediate-term results of this ongoing trial. 
Methods: Between September 1993 and August 1998, 28 patients received 
concurrent heart transplantation and infusion of donor bone matTOW at 3.0 x 
108 cells/kg (study group). Twenty-four contemporaneous heart recipients 
who did not receive bone marrow served as controls. All patients received an 
immunosuppressive regimen consisting of tacrolimus and steroids. 
Results: Patient survival was similar between the study and control groups 
(86% and 87% at 3 years, respectively). However, the proportion of patients 
free from grade 3A rejection was higher in the study group (64% at 6 
months) than in the control group (40%; P = .03). The prevalence of coro-
nary artery disease was similar between the two groups (freedom from dis-
ease at 3 years was 78% in study patients and 69% in controls). Similar pro-
portions of study (18%) and control (15%) patients exhibited in vitro 
evidence of donor-specific hyporesponsiveness. 
,Conclusions: The infusion of donor bone marrow reduces the rate of acute 
rejection in heart recipients. Donor bone matTOW may play an important role 
in strategies aiming to enhance the graft acceptance. (J Thorac Cardiovasc 
Surg 2000; 119:673-81 ) 
We previously reported that donor cells of bone mar-
row lineages were widely distributed at a low level in 
organs of long-surviving recipients of liver l and kidney 
transplants.2 Furthermore, this phenomenon of donor 
microchimerism was present in some recipients who were 
weaned from immunosuppression prospectively. 
Subsequently, this phenomenon also occurred in recipi-
ents of other organs including hearts3 and lungs,4 and 
donor microchimerism was found to be associated with a 
lower incidence of chronic rejection in lung4 and in com-
bined kidney and pancreas5 transplant recipients. To aug-
ment donor cell microchimerism with the aim to enhance 
long-term allograft survival, to attenuate the incidence of 
acute and chronic rejection, and to reduce the need for 
maintenance immunosuppression, we initiated a prospec-
tive trial combining the infusion of unmodified donor 
bone matTow with heart transplantation. Reported herein 
are the intermediate-term results of this trial. 
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Patients and methods 
The Institutional Review Board of the University of 
Pittsburgh approved this study on July 14, 1993, and informed 
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Table I. Demographics of heart recipients 
Variables BM + heart Heart alone P value 
n 28 24 
Recipient's age (y) 49.8 ± 11.1 53.6 ± 8.2 .3 
Donor's age (y) 28.2 ± 11.0 31.3 ± 11.9 .3 
Sex (male/female) 26:2 20:4 .4 
Donor ischemic time 184.3 ± 65.6 219.0 ± 52.4 .04 
(min) 
MHC mismatch 5.0 ± 0.8 5.0± 1.0 .9 
Follow-up duratiou (d) 844 ± 506 825 ± 372 .3 
BM, Bone marrow; MHC, major histocompatibility complex. 
consent forms were obtained from all patients. Between 
September 1993 and August 1998, 28 patients received com-
bined infusion of donor bone marrow and heart transplanta-
tion (study group). In addition, unavailability of consent to 
retrieve bone marrow resulted in the accrual of 24 contempo-
raneous heart transplant recipients as controls. The demo-
graphic information is depicted in Table I. Except for the 
longer donor ischemic time in thc control group, the two 
groups are comparable in age, sex, major histocompatibility 
complex (MHC) mismatch, and the duration of follow-up. All 
patients underwent primary orthotopic heart transplantation, 
without cytoablative or cytoreductive conditioning. 
Furthermore, none of these patients had a positive lymphocy-
totoxic crossmatch. 
Bone marrow preparation. Donor bone marrow cells 
were isolated from thoracolumbar vertebrae as described 6 
They were infused (3-6 x 108 cells/kg body weight) into the 
patient within 2 hours after preparation and between 6 and 10 
hours after revascularization of the heart. 
Immunosuppression. The immunosuppression regimen 
consisted of tacrolimus (FKS06, Prograf; Fujisawa USA, 
Deerfield, Ill) and steroids, as previously described.7 Two 
months after transplantation, if there was no evidence of sig-
nificant rejection by endomyocardial biopsy, systematic 
prospective steroid reduction (by 2.S- to S-mg decrements) 
was initiated in all patients. Azathioprine (Imuran; Burroughs 
Wellcome, Research Triangle Park, NC; 2 mg/kg per day) or 
mycophenolate mofetil (CellCept; Roche Laboratories, 
Nutley, NJ; 2 g per day) was added in case of recurrent rejec-
tion or renal dysfunction (serum creatinine level> 2.0 mg/dL) 
necessitating a reduction of the tacrolimus dose. 
Monitoring and treatment of rejection. Surveillance for 
rejection consisted of weekly endomyocardial biopsies dur-
ing the first month, monthly for the next 3 months, and every 
3 months thereafter during the first year after transplantation. 
Subsequently. biopsies were performed semiannually. In 
addition, endomyocardial biopsies were performed whenever 
clinically indicated. The severity of acute rejection was grad-
ed according to the criteria of the International Society for 
Heart and Lung Transplantation.8 Rejection was treated ini-
tially with steroid boluses (1 g methylprednisolone per day 
for 3 days), whereas OKT3 was reserved for steroid-resistant 
rejection. 
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Detection of chimerism. All recipients were evaluated for 
the presence of donor chimerism in their peripheral blood by 
flow cytometry? and polymerase chain reaction (PCR)7.9 
Blood samples (20 mL) from the patients were obtained on 
days 0 (time of transplantation), IS, 30, and 60 and every 
other month thereafter. For cytometric analysis, values of cir-
culating donor cells of less than 0.5% were considered below 
the level of sensitivity. In this latter group of patients, quali-
tative PCR was subsequently used to serially evaluate the 
presence of donor cell chimerism. In some female recipients 
who had received a male heart, donor (male) DNA in a test 
sample was quantified by means of the nested PCR method.9 
Immune monitoring. The recipient's immune status was 
assessed before and serially after transplantation by mixed 
lymphocyte reaction, mitogen response assay (proliferative 
responses of the recipient's peripheral blood leukocytes to 
concanavalin A, and phytohemagglutinin), and lymphocyte 
growth assay (propagation of lymphocytes [rom endomyo-
cardial biopsy specimens), as previously reported. 10,1 I 
Statistical analysis. Continuous variables were expressed 
as mean ± standard deviation (SO) and compared by means 
of the t test or Mann-Whitney U test when appropriate. 
Differences in proportions were compared by means of the X2 
or Fisher exact tests. Survival, freedom from acute rejection, 
and freedom from coronary artery disease were estimated by 
the Kaplan-Meier method and compared by means of the log-
rank test. The stepwise Cox proportional hazard method was 
used for multivariate analyses of influences of demographic 
and other risk factors on outcomes. For the analysis of the 
levels of chimerism over time, we used the SAS PROC 
MIXED analysis of variance software (Littell RC, Milliken 
GA, Stroup WW, Wolfinger RD: SAS system for mixed mod-
els, SAS Institute Inc, Cary, NC, 1996). This software 
enables us to analyze longitudinal data with missing values. 
Results 
Clinical course and patient survival. The infusion 
of donor bone man-ow was well tolerated. None of the 
recipients had graft-versus-host disease or complica-
tions related to the infusion of donor bone marrow. The 
3-year patient survivals were 87% and 86% in the con-
trol and study groups, respectively (P = .9, Fig 1). Four 
study patients died during the follow-up period of per-
forated gastric ulcer, pulmonary embolism, post-trans-
plantation lymphoproliferative disease, and multiple 
organ system failure from noncompliance with the 
treatment protocol. In the control group, 3 died, 2 of 
infection (l viral and 1 bacterial) and I of post-trans-
plantation lymphoproliferative disease. 
Immunosuppression profiles. At last follow-up 
contact or at the time of death, the level of tacrolimus, 
the dose of prednisone, the number of patients receiv-
ing prednisone, and the number of patients requiring a 
third immunosuppressant (either azathioprine or 
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Fig 1. Patient survival (Kaplan-Meier estimates) after heart transplantation between bone marrow and control 
groups. BM, Bone marrow; CI, confidence interval. 
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Fig 2. Freedom from grade 3A rejection (Kaplan-Meier estimates) after heart transplantation between bone mar-
row and control groups. BM, Bone marrow; CI, confidence interval. 
mycophenolate mofetil) were similar between the 
study and control groups (Table II). 
Acute cellular rejection. The freedom from grade 3A 
rejection at 6 months after transplantation was signifi-
cantly lower (P = .03) in control patients (40%) than in 
those who received bone marrow (64%; Fig 2). The infu-
sion of donor bone marrow seems to have its impact 
early after transplantation. During the first 6 months 
after transplantation, the average number of episodes of 
grade 3A rejection per patient was 1.4 ± 0.2 and 0.6 ± 
0.2 in the control and study groups, respectively (P = 
.02). However, this salutary effect disappears in the sub-
sequent follow-up, with the rates of 3A rejection 
approaching 0.1 ± 0.1 and 0.2 ± 0.1 in the control and 
study groups, respectively. Using the stepwise Cox pro-
portional hazard method to assess the int1uence of vari-
ous factors, which include age (donor and recipient), 
sex, ischemic time, MHC matching, tacrolimus level, 
and bone marrow infusion on acute rejection, we found 
that donor bone marrow infusion is the only independent 
prognostic factor that reduces acute rejection (P = .03; 
risk ratio = 2.42; 95% confidence intervals = 1.08-S.4l). 
676 Pham et at 
100 
90 
:i< 0 
Cl 80 
« 
0 
:; 70 
0 
- o·fJIt5·1" o. 
--I! 
. 
---
p= 0.6 
-
The Journal of Thoracic and 
Cardiovascular Surgery 
April 2000 
.<: 
'i 60 o ••• • ·0 • • ·0 
c::: 
0 50 Time (year) :e 
0 
a. 40 Group 1.0 2.0 3.0 4.0 e 
D- 8M (n=21) 95% 86% 86% 86% CD 30 > (95%CI) (71-99) (59-96) (59-96) (59-96) ~ 
""5 20 ••••• No 8M (n=13) 92% 92% 62% 62% E 
'" 
(95%CI) (64-99) (64-99) (17-93) (17-93) 0 10 
0 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 
Time after transplantation (year) 
Fig 3. Freedom from allograft coronary artery disease (Kaplan-Meier estimates) between bone marrow and con-
trol groups. BM, Bone marrow; CI, confidence interval; CAD, coronary artery disease. 
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Fig 4. Levels of donor cell chimerism in recipients' peripher-
al blood leukocytes. Donor cell chimerism was detected in 
the peripheral blood leukocytes of heart recipients by now 
cytometry. Each circle represents one patient. Levels below 
0.5% were considered not detectable. There was a marginal 
difference (P = .08) in the overall levels of chimerism 
between the study and control groups (analysis of variances 
for repeated measures). However, chimerism persisted much 
longer in the study group (P = .008). During the first 2 
months after transplantation, the bone marrow group had a 
higher proportion of patients with detectable chimerism. 
Asterisk (*) indicates P < .05. 
Allograft coronary artery disease. Allograft coro-
nary artery disease after transplantation was defined as 
luminal irregularity and coronary stenosis seen on a 
coronary angiogram or diffuse arteriopathy at autopsy. 
Table II. Immunosuppression profiles of heart recipi-
ents with or ,vithout donor bone marrmv infusion 
Immunosuppressioll BM + heart Heart alone 
FK level (ng/mL) 12.7±4.3 12.8 ± 4.4 
Prednisone dose (mg/d) 5.6 ± 5.8 8.3 ± 5.9 
Patients on prednisone 17128 (61%) 14/24 (58%) 
Patients on a 3rd drug' 20/28 (71%) 14/24 (58%) 
Expressed as mean ± -.tandard deviation, when appropriate. 
Mann· Whitney U lest. 
'Either azathioprine or rnycophenolate mofa!i!. 
P value 
.9 
.07t 
.9 
.3 
In 34 patients in whom allograft coronary arteries 
could be evaluated, the freedom from coronary artery 
disease at 3 years after transplantation was 69% (con-
trol group, n = 13) and 78% (study group, n = 21) (P = 
.9) (Fig 3). 
Donor cell chimerism. Detection of donor cell 
chimerism was initially carried out by flow cytometric 
technique, which can detect chimerism at a level of one 
donor cell in 200 recipient cells (0.5%) and has been 
shown to correlate well with the induction and mainte-
nance of tolerance in experimental models. 12 In patients 
whose levels of donor cells fall below this threshold. 
molecular detection of donor human leukocyte antigens 
by peR (which could detect an equivalent of one donor 
cell in 105 recipient cells) was performed. 
Flow cytometric analyses were feasible (when appro-
priate antibodies to disparate donor HLA antigens were 
available) in 16 study patients and in 15 controls. 
Overall, the level of donor chimerism was low «3.0%) 
(Figs 4 and 5). There was a marginal difference (P = 
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B c 
Anti Donor Class I 
Fig 5. Donor chimerism in the peripheral blood leukocytes of a heart recipient who received donor bone marrow 
infusion. Recipient cells were stained with a primary mouse antibody against human MHC class I antigen, then 
counterstained with fluorescein isothiocyanate (FITe) conjugated goat anti-mouse secondary antibody, and ana-
lyzed with an EPICS Elite flow cytometer (Coulter Corp, Hialeah, Fla). A, Before transplantation. Band C, One 
and 6 months after transplantation. The number in the right lo\\'er quadrant indicates the percentage of donor cells. 
PE, Phycoerythrin. 
Table III. Prevalence of donor chimerism * in peripheral 
blood leukocytes of heart recipients 
Time (mo) BM + heart Controls P value 
0.5-2 1II13 (85%) 4110 (40%) .006 
3-5 5/9 (56%) 3/8 (38%) .6 
6-8 7112 (58%) 1/8 (13%) .07 
9-11 6/8 (75%) 4/g (50%) .4 
12-14 4/9 (44%) 317 (43%) 1.0 
15-20 219 (22%) 3/8 (38%) .6 
8M, Bone marrow. 
"'By flow cytomdry, chimerism is defined as having at least 0.5% or donor 
cells. 
. 08) in the overall levels of chimerism between the 
study and control groups. However, the pattern of 
chimerism development was significantly different 
between the two groups (P = .008), with chimerism 
persisting much longer in the study group. During the 
first 2 months after transplantation, the bone marrow 
group had a higher proportion of patients with 
detectable chimerism. However, this difference did not 
persist beyond 2 months after transplantation (Table 
III). In both groups, the level of donor chimerism was 
higher in the early postoperative period and decreased 
with time. By 14 months after transplantation, 
chimerism became virtually undetectable by flow 
cytometry, suggesting that its levels had declined below 
the threshold of detection for this technique (Fig 4). 
Due to a lack of appropriate primers for the MHC 
class Ii in some donor-recipient pairs, detection of 
Table IV. Frequency of endomvocardial biopsy 
growth in control and bone marr01-)) recipients 
Period after 
transplantation BM + heart Controls 
Ot06mo 
No. of patients with 27 19 
biopsy 
Patients with no growth 8 (30%) 9 (47%) 
6to 12mo 
No. of patients with 19 14 
biopsy 
Patients with no growth 13 (68%) 6 (43'J,,) 
8M. Bone marrow . 
P value 
.22 
.17 
chimerism by qualitative PCR was feasible in only 14 
study and 13 control patients. The prevalence of donor 
cell chimerism as determined by qualitative PCR on the 
most recent blood sample was higher (13114; 93%) in 
the study group than in the control group (9113; 69%), 
but this difference did not reach statistical significance 
(P = .2). Tn 2 study and 2 control female recipients 
receiving male hearts, the levels of donor cell 
chimerism were serially determined by nested PCR.9 As 
was observed for recipients of other organs,9 the levels 
of chimerism were at least 2 logs higher in the study 
patients than in the control patients (data not shown). 
Immune modulation 
Mixed leukocyte reaction. Immune monitoring by 
mixed leukocyte reaction was possible (only when 
donor splenocytes were available) in 14 control and 16 
study patients. Proliferative responses of recipients' 
678 Pham et al 
peripheral blood leukocytes to donor splenocytes at 
various times after transplantation were compared with 
those obtained in pretransplantation samples. No dif-
fcrence in donor-specific immune modulation was dis-
cerned between the two groups for up to I year after 
transplantation. Eighteen percent of patients in the 
study group and 15% in the control group had donor-
spccific hyporesponsiveness (data not shown). 
Lymphocyte growth assay. We have demonstrated 
that a positive lymphocyte growth assay in endomyo-
cat'dial specimens that have low-grade rejection (grade 
< 2) is highly predictive of subsequent high-grade 
rejection (grade > 2). II Therefore the lymphocyte 
growth assay may be used as a surrogate marker of the 
recipient's immune reactivity toward the graft. The 
absence of lymphocyte growth from the endomyocar-
dial specimens indicates less alloreactivity toward the 
graft and vice versa. During the first 6 months after 
transplantation, no difference was noted in the propor-
tion of patients with negative lymphocyte growth assay 
(non-grower) between the study and control groups 
(30% vs 47%, respectively; Table IV). In the subse-
quent 6 months (6-12 months after transplantation), the 
proportion of non-growers was higher (although not to 
a statistically significant degree) in the study group 
than in the control group (68% vs 43%, respectively; 
Table IV). This observation suggested a trend toward 
less alloreactivity in recipients who had received con-
comitant bone marrow infusion. 
Discussion 
The recognition that bone marrow chimerism is asso-
ciated with immunologic tolerance dates back more 
than half a century. Billingham and associates l3 
observed that adult freemartin cattle (dizygotic twins 
that share a common placenta during intrauterine life 
and possess erythrocyte chimerism) permanently 
accepted each other's skin grafts. These investigators 
were able to duplicate this observation in experimental 
models by inoculating hematopoietic cells obtained 
from MHC-disparate donors into fetal mice. 14 
Subsequently, chimerism with donor-specific tolerance 
was achieved in adult animals by preconditioning the 
host with total body irradiation, 12 total lymphoid irradi-
ation,15 and the use of antilymphocyte globulin. 16 
Although clinical translation of tolerant models 
requiring recipient conditioning with total lymphoid 
radiation 17 and total body radiation (I1dstad ST, person-
al communication, 2000) have been attempted, it is the 
Monaco model,16 which used antilymphocyte globulin 
induction therapy, that has been exploited extensively 
in clinical transplantation. Monaco and associates l8 
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were the first to apply this strategy to a renal recipient 
in 1976. The first large-scale clinical trial in which the 
Monaco model was used was carried out in cadaveric 
renal recipients by Barber and colleagues. 19 In this 
study, graft survival was significantly better in the bone 
marrow group than in the controls (90% vs 71 % at I 
year). Other clinical evidence of benefits of bone mar-
row augmentation included a reduced need for 
immunosuppression and a lower acute rejection rate. 
The rationale for the initiation of the current adjuvant 
bone marrow infusion program was based on the dis-
covery by Starzl and coworkers 1,2 that donor cells of 
bone marrow lineages persisted at a low level in the 
peripheral blood, lymphoid organs, and skin of long-
surviving kidney (n = 5; lO-29 years) and liver (n = 25; 
3-22 years) recipients. 1,2 On the basis of these observa-
tions, it was argued that the establishment of 
microchimerism (the presence of a low level of donor 
bone marrow-derived cell in solid organ recipients) 
was perhaps essential for long-term allograft accep-
tance. It was therefore hypothesized that augmenting 
this spontaneously occurring event with perioperative 
donor bone marrow infusion may further enhance the 
acceptance of the graft, especially of those organs that 
are not endowed with a large quantity of passenger 
leukocytes within their interstitium. To test this hypoth-
esis, in December 1992, we6 initiated a trial combining 
donor bone marrow infusion with solid organ trans-
plantation, without recipient preconditioning. 
Following the lead at Pittsburgh, Garcia-Morales and 
associates20 at the University of Miami have adopted a 
modified protocol using multiple infusions of donor 
bone marrow in renal transplant recipients. In this non-
randomized trial, 40 renal transplant recipients who 
received unmodified donor bone marrow infusion were 
compared with 100 contemporaneous control subjects. 
All patients received induction therapy with OKT3 and 
a maintenance immunosuppression regimen consisting 
of tacrolimus and steroids; in some patients mycophe-
nolate mofetil was added as a third drug. Cryo-
preserved bone marrow cells were infused at two inter-
vals: between days 1 and 4 and between days 10 and 14 
after transplantation. The bone marrow recipients had 
higher levels of donor chimerism than control subjects, 
both in their peripheral blood and in their bone marrow. 
Notably, the levels of donor chimerism (especially 
CD3+ and CD34+ cells) were I (}-fold higher in the bone 
marrow compartment than in the peripheral blood. 
Patients receiving bone marrow also had more mitigat-
ed humoral and cellular immune responses than did the 
control patients. Using the same induction and mainte-
nance immunosuppression protocol as employed by 
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Garcia-Morales and associates,20 Ricordi and cowork-
ers21 have reported that liver allograft survival was sig-
nificantly higher in patients receiving multiple infu-
sions than in those receiving a single perioperative 
infusion of donor bone marrow. 
The intermediate-term results in heart recipients 
reported herein confirm our preliminary data7 that the 
infusion of unmodified donor bone marrow concurrent-
1y with heart transplantation is well tolerated and safe. 
There was no evidence of graft-versus-host disease and 
no complication that was related specifically to the 
infusion of donor bone marrow. There was an increase 
in the level of chimerism in the bone marrow recipients 
as compared with the controls, a finding reminiscent of 
that observed in the recipients of other organ allo-
grafts. 9 Despite the similarity in the immunosuppres-
sion profiles, acute rejection was less prevalent in bone 
marrow recipients than in the control patients. 
Furthermore, there was a trend toward less alloreactiv-
ity toward the graft, as assessed by the lymphocyte 
growth assay. in the study group. Although not statisti-
cally significant. the freedom from allograft coronary 
artery disease at 3 years after transplantation was high-
er in bone marrow recipients (78% vs 69% in the con-
trols). It is conceivable that with a longer duration of 
follow-up and a larger sample size, this difference may 
approach statistical significance. 
The mechanism that accounts for the lower rejection 
rate in the bone marrow group remains to be elucidat-
ed. However, it is conceivable that donor bone marrow 
cells may have down-regulated the recipient's immune 
system by suppressing the development of cytotoxic T 
cells. In vitro studies by Mathew,22 Rachamin,23 and 
their associates have demonstrated that human bone 
marrow cells inhibited both the proliferative and cyto-
toxic responses in a dose-dependent manner. These in 
vitro data supporting the existence of a veto mecha-
nism, which was originally described by Miller,24 have 
been further corroborated by in vivo observations in 
nonhuman primates25 and in human beings.26 
Another possible mechanism by which the donor bone 
marrow cells could have modulated the recipient's 
immune system is via clonal exhaustion of donor-reac-
tive cells. It is possible that the infused donor bone mar-
row cells, which can readily disseminate throughout the 
recipient's body, expose the recipient's immune cells 
with an excess of donor antigens, causing clonal activa-
tion followed by deletion of the donor-reactive T (and 
possibly B) cells. This activation-induced tolerance, 
which occurs exclusively in lymphoid organs or orga-
nized lymphoid collections, is analogous to the situation 
in which all antigen-specific T cells are deleted when the 
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host is exposed to an excess load of that particular anti-
gen, such as a generalized infection with noncytopathic 
viruses.27•28 This mechanism of tolerance is elegantly 
described by Zinkemagel27 in the case of lymphocytic 
choriomeningitis infection in mice. In the realm of trans-
plantation tolerance, the commonality between the toler-
ance to infectious agents and transplanted allografts has 
been discussed in detail by Starzl and Zinkemagel.28 
Of particular interest is the fact that even though 
acute rejection is less prevalent in the bone marrow 
group, there was no in vitro evidence of immune mod-
ulation in these patients as assessed by I-way mixed 
leukocyte reaction. The discrepancy between the in 
vivo and in vitro responses as observed in this study is 
not unique. This dichotomy between in vivo hypore-
sponsiveness (organ acceptance) and in vitro alloreac-
tivity, which has been referred to as "split toler-
ance,"29.30 further heightens the need for developing 
more reliable in vitro techniques that would be more 
predictive of graft tolerance. 
In summary, the intermediate-term data from this cur-
rently ongoing clinical trial indicate that the infusion of 
unmodified donor bone marrow concurrently with heart 
transplantation is safe and is associated with an 
increased level of donor cell chimerism. Furthermore, 
the early immunologic events after cardiac transplanta-
tion appear to have been altered by the infusion of donor 
bone marrow. When compared with the control patients, 
bone marrow recipients had less acute rejection and less 
alloreactivity (albeit not to a statistically significant 
degree) by the lymphocyte growth assays. Although the 
eventual salutary effect of donor-specific bone marrow 
infusion in heart recipients remains speculative, it is 
apparent that donor bone marrow infusion is feasible, 
safe, and associated with less rejection. Inclusion of 
concomitant infusion of donor bone marrow in future 
strategies aiming to enhance the acceptance of cardiac 
allografts must be seriously considered. 
We thank Robert Duncan, PhD, Professor of Epidemiology 
and Public Health, University of Miami, for his assistance 
with statistical analyses. 
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Discussion 
Dr Verdi J. DiSesa (Chicago. Tlli. Dr Pham and his col-
leagues have shown that unmodilied donor bone marrow 
administered intravenously shortly after heart transplantation 
can reduce the incidence of moderate to severe rejection. This 
is important since it represents a shift from a strategy of trans-
plant immune modulation based on nonspecific pharmacolog-
ic immune suppression to one whereby biologic manipulations 
are used to induce donor-specific hyporesponsiveness. This is 
Sir Peter Medawar's actively acquired immune tolerance, and 
I congratulate Dr Pham and his coauthors on an elegantly pre-
sented report of their attempts to produce it in patients. 
In heart transplantation, it is not the usual practice to per-
form prospective histocompatibility tissue antigen matching, 
and the authors have not done so here. However, we and oth-
ers have shown that fortuitous MHC matching, identified ret-
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rospectively, can produce reductions in rejection similar to 
those observed in this study. 
The authors have reported average MHC mismatching to 
be the same in both groups, but have they looked at subsets of 
patients within each group that may have had fortuitous 
matching? Might this have played a role in the differences in 
rejection that they saw? 
Transient chimerism in their study was also seen in patients 
treated conventionally without bone marrow infusions. Why 
did the authors not include a conditioning regimen, such as 
irradiation, so as to enhance the degree and durability of bone 
marrow engraftment? What is their explanation for the failure 
to see a reduced proliferative response in the in vitro immune 
assays? 
Finally, what do the authors think about the importance of 
the nature of chimerism? Is it low level of all lineages of 
donor hematopoietic cells that is important, or perhaps the 
Illere presence of any lineage of circulating donor cells? Does 
it make any difference? 
Dr Pham. Thank you, Dr DiSesa, for your comments. To 
answer your first question regarding a subset analysis of 
patients with MHC match, the number of patients in our 
study is too small to do that. Dr Joshua Miller's group at the 
University of Miami had identified a subset of renal recipi-
ents with DR match who received donor bone marrow infu-
sion. These recipients had better engraftment of the donor 
cells than those without DR Illatch. Furthermore, rejection 
was less common in these recipients. Actually, 10 of 10 
patients of that group had never had rejection. 
The second question is related to the conditioning of the 
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recipient: Why did we not give the recipient radiation or any 
other cryoablative conditioning? The most robust means to 
induce tolerance is the mixed chimerislll achieved by radia-
tion that allows the engraftment of the stem cells of the bone 
marrow. This type of tolerance had been reported initially by 
Medawar and later by Suzanne Ildstad and David Sachs. 
However, convincing the institutional review board to allow 
us to use radiation initially was difficult. Furthermore, the 
rationale of the current study is different from the classic 
radiation chimera model. In this study we tried to enhance the 
naturally occurring microchimerism. We do not know 
whether donor bone marrow infusion will enhance graft 
acceptance or not: A great body of experimental data suggests 
that it would work. In the 1970s, Dr Monaco from Boston 
showed that this form of treatment induced tolerance in the 
small animal models. Subsequently, other groups have shown 
the same results in the larger animal. 
The discrepancy between the in vitro immune response ver-
sus the in vivo response (ie, graft acceptance) has been well 
described in animal models. This phenomenon is called split 
tolerance, where there is acceptance of the organ but no toler-
ance by in vitro (mixed lymphocyte reaction or cell-mediated 
Iymphocytotoxity) testing. It reflects the fact that a better or 
more sensitive technique is needed to detect tolerance. 
The stem cell is very important for the induction of toler-
ance because, if engrafted, it allows the propagation of donor 
cells and donor antigens that allow clonal deletion of the 
recipient lymphocytes. However, other mechanisms of toler-
ance such as clonal anergy and clonal exhaustion may also 
play an important role in enhancing graft acceptance. 
